


PHARMACEUTICAL 2022

Aprea Therapeutics Inc. Rank 360 of 475





PHARMACEUTICAL 2022

Aprea Therapeutics Inc. Rank 360 of 475

The relative strengths and weaknesses of Aprea Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aprea Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Aprea Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 201% points.

The company's Economic Capital Ratio, given in the ranking table, is -302%, being 26% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	56,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,316
Liabilities, Non-Current	0
Other Assets	215
Other Compr. Net Income	-322
Other Expenses	0
Other Liabilities	0
Other Net Income	319
Property and Equipment	24
Research and Development	23,896
Revenues	0
Selling, General and Administrative Expense	13,550

Output Variable	Value in 1000 USD
Assets	56,823
Liabilities	7,316
Expenses	37,446
Stockholders Equity	49,507
Net Income	-37,127
Comprehensive Net Income	-37,288
Economic Capital Ratio	-302%